ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1420

Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus

Peter Izmirly1, Mimi Kim2, Marie Samanovic-Golden3, Ruth Fernandez Ruiz4, Sharon Ohana3, Alexis Engel5, Kristina Deonaraine1, Mala Masson4, Xianhong Xie6, Amber Cornelius4, Ramin Herati4, Rebecca Haberman4, Jose Scher1, Allison Guttmann3, Rebecca Blank7, Ben Plotz3, Mayce Haj-Ali4, Brittany Banbury3, Sara Stream8, Ghadeer Hasan3, Gary Ho3, Paula Rackoff7, Ashira Blazer3, H. Michael Belmont3, Amit Saxena3, Mark Mulligan4, Robert Clancy4 and Jill Buyon3, 1New York University School of Medicine, New York, NY, 2Albert Einstein College of Medicine, Larchmont, NY, 3NYU School of Medicine, New York, NY, 4NYU Grossman School of Medicine, New York, NY, 5NYU Langone Health, New Yok, NY, 6Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, 7New York University, New York, NY, 8NYU Langone Health, New York, NY

Meeting: ACR Convergence 2021

Keywords: COVID-19, immunosuppressants, Systemic lupus erythematosus (SLE), Vaccination

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: COVID-19 Vaccine Experience & Translational Science (1420–1423)

Session Type: Abstract Session

Session Time: 9:00AM-9:15AM

Background/Purpose: Since the Phase 3 clinical studies of all three COVID-19 vaccines excluded patients on immunosuppressants or immune-modifying drugs within 6 months of enrollment, data on SLE is virtually absent. Given the potential of disease flares following immunization, there has been hesitancy for vaccination in patients with rheumatic diseases, including those with SLE. Accordingly, this study was initiated to evaluate seroreactivity and disease flares after COVID-19 vaccination in a multi-ethnic/racial cohort of patients with SLE.

Methods: 90 patients from the NYU Lupus cohort and 20 healthy controls who received a complete COVID-19 vaccine schedule were included. IgG seroreactivity to the SARS-CoV-2 Spike receptor-binding domain (RBD) measured by ELISA and SARS-CoV-2 microneutralization assay were used to evaluate B cell responses, and IFN-γ production to assess T cell responses as measured by ELISpot. Disease activity was measured by the hybrid SLE disease activity index (SLEDAI) and flares assigned by the SELENA/SLEDAI flare index.

Results: Overall, the mean titers of post-vaccine antibody levels were lower in SLE patients compared to controls (Figure 1). Specifically, 26 (29%) patients generated IgG antibody responses to the SARS-CoV-2 Spike RBD that fell below that of the lowest response obtained for the controls (≤100) (Table 1). Factors in the SLE patients which significantly associated with poor responses in bivariate analysis included prednisone use in combination with at least 1 immunosuppressant (p=0.049), a combination of two immunosuppressants (p=0.01), prednisone use (p=0.021), mycophenolate mofetil or mycophenolic acid use (p=0.001), receiving the Jansen/Johnson & Johnson vaccine (p=0.04) and a normal anti-dsDNA level prior to vaccination (p=0.03); only antimalarial use associated with a positive response (p< 0.0001). A logistic regression model of predictors of ELISA response >100 among SLE patients showed that taking antimalarials or no medications [OR 11.8 (95%CI 2.9, 48.5, p=0.0006)], and elevated anti-dsDNA prior to vaccination [OR 7.8 (95%CI 2.9, 48.5, p=0.0047)] are independent predictors of vaccine response. IgG seroreactivity to the SARS-CoV-2 Spike RBD strongly correlated with the SARS-CoV-2 microneutralization assay (R=0.81; p< 0.0001, Figure 1) and correlated with the ELISpot (R=0.57; p=0.0135). In a subset of patients with poor antibody responses, IFN-γ production was likewise diminished. In aggregate, there was no change in post-vaccination SLEDAI scores compared to those measured pre-vaccination. Only 11% of patients were considered to have post vaccination disease flares; 1% severe (further details in Table 2).

Conclusion: In a multi-ethnic/racial study of SLE patients nearly 30% had a low response to the COVID-19 vaccine. Having a normal anti-dsDNA and taking any medications other than antimalarials independently associated with a decreased vaccine response. Reassuringly, disease flares were rare. While minimal protective levels remain unknown, these data suggest protocol development to assess efficacy of booster vaccination.

MTX=Methotrexate, MMF=mycophenolate mofetil, HCQ=hydroxychloroquine, RTX=Rituximab


Disclosures: P. Izmirly, Momenta/Janssen, 1; M. Kim, None; M. Samanovic-Golden, None; R. Fernandez Ruiz, None; S. Ohana, None; A. Engel, None; K. Deonaraine, None; M. Masson, None; X. Xie, None; A. Cornelius, None; R. Herati, CareDx, 5; R. Haberman, Janssen, 1; J. Scher, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, AbbVie, 2, Sanofi, 2, Kaleido, 2, UCB, 2; A. Guttmann, None; R. Blank, None; B. Plotz, None; M. Haj-Ali, None; B. Banbury, None; S. Stream, None; G. Hasan, None; G. Ho, None; P. Rackoff, None; A. Blazer, Glaxo Smith Kline, 1, 2, Novartis, 1; H. Belmont, None; A. Saxena, Bristol Myers Squibb, 1, Eli Lilly and Company, 1, Glaxo Smith Kline, 1, Kezar Life Sciences, 1, Astra Zeneca, 1, Jannsen, 1; M. Mulligan, Meissa Vaccines, 1, Eli Lilly, 5, Pfizer, 5, Sanofi, 5; R. Clancy, None; J. Buyon, Bristol Myers Squibb, 1, GlaxoSmithKline, 2, Janssen, 2, Ventus, 2, Equillium, 2.

To cite this abstract in AMA style:

Izmirly P, Kim M, Samanovic-Golden M, Fernandez Ruiz R, Ohana S, Engel A, Deonaraine K, Masson M, Xie X, Cornelius A, Herati R, Haberman R, Scher J, Guttmann A, Blank R, Plotz B, Haj-Ali M, Banbury B, Stream S, Hasan G, Ho G, Rackoff P, Blazer A, Belmont H, Saxena A, Mulligan M, Clancy R, Buyon J. Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-sars-cov-2-vaccine-response-in-a-multi-racial-ethnic-cohort-of-patients-with-systemic-lupus-erythematosus/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-sars-cov-2-vaccine-response-in-a-multi-racial-ethnic-cohort-of-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences